Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:33:00.160Z.
Consensus retrieved: 2026-10-06T16:33:16.121Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:33:00.160Z.
Quote observation: 2026-10-06T18:27:55.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2d4dff4c736cbb4e00c259d8a24cf863f8d27a03b54b82d918c664c72978b9aa
Forward PE Ratio (N/A) = Dated Quote Price ($0.34) / Consensus Forward EPS ($-0.78)
FORWARD PE RATIO
N/A
Senti Biosciences, Inc.
Market Cap
$10.58M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Senti Biosciences, Inc. (SNTI) | $10.58M | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.58M | N/A |
| Pluri Inc. (PLUR)vs › | $10.59M | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.51M | N/A |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.41M | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $10.38M | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.26M | N/A |
| Caring Brands, Inc. (CABR)vs › | $11.00M | N/A |
| BioVie Inc. (BIVI)vs › | $11.01M | N/A |
| Cerenome, Inc. (CNSY)vs › | $11.05M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $0.34, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.78 | $-0.78 – $-0.78 | 1 | n/m |
| 2027-12-31 | $-0.96 | $-0.96 – $-0.96 | 1 | n/m |
| 2028-12-31 | $-1.61 | $-2.22 – $-1.00 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
